Answers are grounded in this paper and cite their sources.
The European Partnership for Alternative Approaches to Animal Testing (EPAA) held the “New Approach Methodologies (NAMs) User Forum Kick-Off Workshop”, at the European Chemicals Agency (ECHA), Helsinki, Finland on 7–8 December 2023. The aim of the User Forum was to gain insight into the regulatory use of NAMs, with a particular reference to Next Generation Risk Assessment (NGRA), for chemical safety assessment. To achieve this, presentations summarised the learnings and experiences of previous EPAA Skin Sensitisation User Forums as well as that of the European Commission's Scientific Committee on Consumer Safety (SCCS). The findings of five case studies were summarised that illustrated the use of NAMs. The presentations and subsequent discussions allowed for learnings and insights to be compiled from all stakeholders with regard to the use of NAMs. Recommendations for the regulatory use of NAMs in NGRA were made, namely for exposure assessment; hazard identification; using tiered and targeted testing strategies; performing risk assessment using NAM data; the practical implementation of NAMs; the use of -omics technologies; and the needs for capacity building and training. The EPAA User Forum provided an open platform for safety assessors to share learnings and experiences. Recommendations for the format and topics of future EPAA User Forums were also made. • Broad stakeholder support exists for the regulatory use of NAMs for chemical safety. • NAMs are applicable in assessment of internal exposure and hazard identification. • Tiered testing strategies allow NAMs to be used in risk assessment. • Applicability, confidence and practical implementation of NAMs are required. • Areas to improve regulatory uptake of NAMs are identified.
No takes yet. Share an insight, caveat, or question.
Cronin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: